OBJECTIVES: The aim of the study was to identify gene polymorphisms that confer susceptibility to metabolic syndrome in order to allow reliable assessment of genetic risk for this condition. METHODS AND RESULTS: The study population comprised 1788 unrelated Japanese individuals (1033 men, 755 women), including 1017 subjects with metabolic syndrome (634 men, 383 women) and 771 controls (399 men, 372 women). The genotypes for 158 polymorphisms of 133 candidate genes were determined with a method that combines the polymerase chain reaction and sequence-specific oligonucleotide probes with suspension array technology. Multivariable logistic regression analysis with adjustment for age, sex, and the prevalence of smoking revealed that the -1131T-->C polymorphism of the apolipoprotein A-V gene (APOA5) was significantly associated with the prevalence of metabolic syndrome, with the C allele representing a risk factor for this condition. A stepwise forward selection procedure demonstrated that APOA5 genotype (CC+TC versus TT) significantly affected the prevalence of metabolic syndrome. The C allele of this polymorphism was associated with an increased serum concentration of triglycerides and a decreased concentration of HDL-cholesterol. CONCLUSIONS: Genotype for APOA5 may prove reliable for assessment of genetic risk for metabolic syndrome.
OBJECTIVES: The aim of the study was to identify gene polymorphisms that confer susceptibility to metabolic syndrome in order to allow reliable assessment of genetic risk for this condition. METHODS AND RESULTS: The study population comprised 1788 unrelated Japanese individuals (1033 men, 755 women), including 1017 subjects with metabolic syndrome (634 men, 383 women) and 771 controls (399 men, 372 women). The genotypes for 158 polymorphisms of 133 candidate genes were determined with a method that combines the polymerase chain reaction and sequence-specific oligonucleotide probes with suspension array technology. Multivariable logistic regression analysis with adjustment for age, sex, and the prevalence of smoking revealed that the -1131T-->C polymorphism of the apolipoprotein A-V gene (APOA5) was significantly associated with the prevalence of metabolic syndrome, with the C allele representing a risk factor for this condition. A stepwise forward selection procedure demonstrated that APOA5 genotype (CC+TC versus TT) significantly affected the prevalence of metabolic syndrome. The C allele of this polymorphism was associated with an increased serum concentration of triglycerides and a decreased concentration of HDL-cholesterol. CONCLUSIONS: Genotype for APOA5 may prove reliable for assessment of genetic risk for metabolic syndrome.
Authors: M Akbarzadeh; T Hassanzadeh; M Saidijam; R Esmaeili; Sh Borzouei; M Hajilooi; H Mahjub; M Paoli Journal: Mol Biol Rep Date: 2012-06-23 Impact factor: 2.316
Authors: Chao Qiang Jiang; Bin Liu; Bernard M Y Cheung; Tai Hing Lam; Jie Ming Lin; Ya Li Jin; Xiao Jun Yue; Kwok Leung Ong; Sidney Tam; Ka Sing Wong; Brian Tomlinson; Karen S L Lam; G Neil Thomas Journal: Eur J Hum Genet Date: 2010-06-23 Impact factor: 4.246
Authors: Kati Kristiansson; Markus Perola; Emmi Tikkanen; Johannes Kettunen; Ida Surakka; Aki S Havulinna; Alena Stancáková; Chris Barnes; Elisabeth Widen; Eero Kajantie; Johan G Eriksson; Jorma Viikari; Mika Kähönen; Terho Lehtimäki; Olli T Raitakari; Anna-Liisa Hartikainen; Aimo Ruokonen; Anneli Pouta; Antti Jula; Antti J Kangas; Pasi Soininen; Mika Ala-Korpela; Satu Männistö; Pekka Jousilahti; Lori L Bonnycastle; Marjo-Riitta Järvelin; Johanna Kuusisto; Francis S Collins; Markku Laakso; Matthew E Hurles; Aarno Palotie; Leena Peltonen; Samuli Ripatti; Veikko Salomaa Journal: Circ Cardiovasc Genet Date: 2012-03-07
Authors: Yae Jung Hyun; Yangsoo Jang; Jey Sook Chae; Ji Young Kim; Jean Kyung Paik; So Yeon Kim; Ju Young Yang; Jose M Ordovas; Young Guk Ko; Jong Ho Lee Journal: Atherosclerosis Date: 2008-12-31 Impact factor: 5.162
Authors: P Hahne; F Krempler; F G Schaap; S M Soyal; H Höffinger; K Miller; H Oberkofler; W Strobl; W Patsch Journal: J Intern Med Date: 2008-06-03 Impact factor: 8.989